Gilead Sciences Inc - $GILD STOCK NEWS

Gilead Sciences, Inc. and Kite, a Gilead Company, will present 18 abstracts at the 2024 ASCO Annual Meeting, showcasing their commitment to developing innovative cancer treatments. The data cover a broad range of cancers, including lung, breast, and gastrointestinal, with highlights on Trodelvy in NSCLC, gastrointestinal pipeline progress, and new CAR T-cell therapy data. The company continues to focus on transforming cancer treatment through groundbreaking research.

Forbes has recognized Gilead as one of America's Best Employers for Diversity. The company's commitment to inclusion and diversity is highlighted, reflecting positive feedback from employees and the community. Gilead Sciences, a biopharmaceutical company, aims to innovate medicines for unmet medical needs globally.

Gilead Sciences, Inc. (Nasdaq: GILD) executives will be speaking at several upcoming investor conferences, showcasing the company's commitment to advancing innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The live webcasts and replays will be available on the company's investors page. Gilead operates globally with headquarters in Foster City, California.

Gilead Sciences announced the FDA approval of an updated label for Biktarvy, a treatment for pregnant people with HIV-1. The label includes additional data from Study 5310, supporting the safety and efficacy of Biktarvy in pregnant individuals with suppressed viral loads. Biktarvy is recognized as an alternative regimen for use during pregnancy and for those trying to conceive, with guidelines recommending its continuation for virologically suppressed individuals who may become pregnant. The label update signifies a significant milestone in HIV treatment research, providing assurance for people of childbearing potential to remain on Biktarvy if pregnant.

Gilead Sciences announced strong first quarter 2024 financial results with a 6% increase in product sales excluding Veklury, totaling $6.1 billion. Biktarvy sales rose by 10% to $2.9 billion, and Oncology sales increased by 18% to $789 million. The CymaBay acquisition led to a $3.9 billion charge impacting diluted EPS. Gilead's total revenue increased by 5% to $6.7 billion, with a significant decrease in diluted EPS due to acquisition-related charges. The company had $4.7 billion in cash as of March 31, 2024.

Gilead Sciences recently published its 2023 Environmental, Social, and Governance (ESG) Impact Report, showcasing its achievements in innovating scientific solutions, advancing health equity, empowering communities, and sustaining the planet. The report highlights Gilead's commitment to creating a healthier world while benefiting people, communities, and the environment.

Gilead Sciences, Inc. (GILD) will release its first quarter 2024 financial results and guidance on April 25, 2024. A webcast will be hosted to discuss the results and provide a business update.

Gilead Sciences emphasizes gender equality with women representing over half of its workforce and a close salary ratio of 99.93:100 globally in 2023. The company is dedicated to developing innovative medicines for unmet medical needs worldwide.

Gilead Sciences receives FDA approval for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years and older, showcasing efficacy and safety in a Phase 2 clinical trial.